Plain-English translation of NCT05007132 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
FIRE-8 is testing whether combining trifluridine/tipiracil with panitumumab works better than combining trifluridine/tipiracil with for treating advanced colorectal cancer. Both combinations pair the same base chemotherapy drug with a different targeted therapy. The trial will randomly assign about 153 patients to one of these two treatment groups to see which works better.
Standard combination chemotherapy can be too harsh for some patients with advanced bowel cancer. This trial explores whether pairing a gentler chemotherapy with targeted therapies might offer a better option for people who cannot tolerate or prefer to avoid intensive multi-drug chemotherapy.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take one of two medication combinations. Both involve taking trifluridine/tipiracil as an oral pill twice daily on specific days, plus intravenous infusions (shots into the vein) of either panitumumab or on days 1 and 15 of each cycle. You will have regular doctor visits and scans to check how well the treatment is working and monitor for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Germany